In this article

MEDVi is a consumer-facing online healthcare brand. A search for the name can lead to weight-management offers, a men’s-health product, support pages, and review sites, so it helps to identify exactly which service you mean.

This overview separates the platform from its medical and pharmacy partners and explains why the product-specific details matter. It also points to a material FDA warning letter rather than allowing the brand’s public presence to stand in for a quality assessment.

THE SHORT ANSWER

MEDVi is an identifiable online platform with several product pathways. Check the exact program and its responsible clinical and pharmacy partners; its FDA warning letter is important context for evaluating claims.

What to know first

  • MEDVi presents an online platform with provider review and pharmacy fulfillment. Its public disclosure names OpenLoop Health and CareGLP-affiliated professional entities in connection with medical care, and identifies several pharmacy partners. Those are provider disclosures, not a license audit conducted by this publication.
  • We did not verify a single current all-inclusive MEDVi weight-loss price from the main page captured for this review. Do not import a price from an older advertisement or a sponsored “review” into your budget without checking the exact offer.
  • The exact prescriber, pharmacy, and prescription still need individual verification.

A brand name can cover different programs

MEDVi presents an online platform with provider review and pharmacy fulfillment. Its public disclosure names OpenLoop Health and CareGLP-affiliated professional entities in connection with medical care, and identifies several pharmacy partners. Those are provider disclosures, not a license audit conducted by this publication.

A material part of this review is the FDA’s February 20, 2026 warning letter addressed to MEDVi, LLC. The letter concerns misleading marketing of compounded semaglutide and tirzepatide, including product labeling and claims that could imply approval. The existence of a real business does not remove those concerns.

Do not assume the terms, phone number, medicine, or clinical screening for one program apply to another. The weight-management service and MEDVi QUAD address different conditions and involve different medication questions.

Sources: MEDVi: provider, pharmacy, and contact disclosures · FDA: MEDVi warning letter, February 20, 2026 · MEDVi QUAD: product and ingredient page

What the FDA letter concerns

The FDA’s February 20, 2026 warning letter to MEDVi LLC dba MEDVi followed review of medvi.io in December 2025. It addresses false or misleading claims involving compounded GLP-1 products, including language implying FDA approval or equivalence and misleading identification of the compounder.

A warning letter documents the agency’s findings described in that letter. It is not proof that every patient’s treatment failed, nor should a general review assume the concerns have been resolved without supporting evidence. Read the actual letter and ask how current materials address it.

Sources: FDA: MEDVi warning letter, February 20, 2026

Identify the agreement you are considering

We did not verify a single current all-inclusive MEDVi weight-loss price from the main page captured for this review. Do not import a price from an older advertisement or a sponsored “review” into your budget without checking the exact offer.

The QUAD erectile-dysfunction page advertises a per-dose amount, but that is a different service from a GLP-1 weight-loss plan. Ask for the quantity, payment schedule, renewal amount, and cancellation terms of the specific product you are considering.

Save the offer page, final checkout summary, and linked terms for the specific product. Some legal links encountered during this research were unavailable; we do not fill that gap with a third-party account of the refund policy.

Sources: MEDVi: provider, pharmacy, and contact disclosures · FDA: MEDVi warning letter, February 20, 2026 · MEDVi QUAD: product and ingredient page

Use the right support route

MEDVi’s general published phone is (323) 690-1564 and email is help@medvi.org. The QUAD page lists a different contact number. Our MEDVi contact guide distinguishes program support from pharmacy numbers.

For a complete evaluation, use the MEDVi legitimacy review, the reputation guide, and the safety questions.

Sources: MEDVi: provider, pharmacy, and contact disclosures · MEDVi QUAD: product and ingredient page

Put this question in the wider picture

Our MEDVi review brings together the company, pricing, care, and pharmacy disclosures. For practical account questions, use MEDVi customer service. A review can help you prepare questions, but it cannot access your order or approve a treatment.

Save the provider’s response alongside the actual offer and agreement. A statement about a general program may not describe the product, payment term, or clinician assigned to you. Recheck time-sensitive details before enrolling or renewing.

Sources & research notes

Checked September 21, 2026. Provider pages document the provider’s own statements; they do not independently establish treatment safety or results. This is desk research, not a product test or clinical review.

  1. MEDVi: provider, pharmacy, and contact disclosuresProvider-published information · Checked September 21, 2026
  2. FDA: MEDVi warning letter, February 20, 2026Regulatory / public agency · Checked September 21, 2026
  3. MEDVi QUAD: product and ingredient pageProvider-published information · Checked September 21, 2026

Read our methodology · Commercial disclosure · Request a correction